Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19

Abstract Immunocompromised patients with prolonged coronavirus disease 2019 symptoms present diagnostic and therapeutic challenges. We measured viral nucleocapsid antigenemia in 3 patients treated with anti-CD20 immunotherapy who acquired severe acute respiratory syndrome coronavirus 2 infection and experienced protracted symptoms. Our results support nucleocapsid antigenemia as a marker of persistent infection and therapeutic response.

[1]  E. Albert,et al.  Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients , 2022, Scientific Reports.

[2]  S. Stowell,et al.  Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection , 2022, medRxiv.

[3]  H. Jarva,et al.  Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection , 2021, Journal of Virological Methods.

[4]  A. Wu,et al.  Diagnostic Value of Nucleocapsid Protein in Blood for SARS-CoV-2 Infection , 2021, Clinical chemistry.

[5]  T. Bedford,et al.  SARS-CoV-2 Variants in Patients with Immunosuppression. , 2021, The New England journal of medicine.

[6]  M. Binnicker.  Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods To Be Surrogates for Replication-Competent Virus , 2021, Journal of clinical microbiology.

[7]  B. Pinsky,et al.  The truth about SARS-CoV-2 cycle threshold values is rarely pure and never simple. , 2021, Clinical chemistry.

[8]  J. Mellors,et al.  Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Joseph M. Johnson,et al.  N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection , 2021, Nature Communications.

[10]  N. E. Babady,et al.  Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer , 2020, The New England journal of medicine.

[11]  E. Fischer,et al.  Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.

[12]  P. Gallian,et al.  Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 , 2020, Blood.